Review
Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors
World J Pharmacol
15(1):113080.
Published online Jan 19, 2026.
doi: 10.5497/wjp.v15.i1.113080
Abstract (2)
|
Core Tip (1)
|
Full Article (HTML) (19)
|
Figures (1-5) (1)
|
Tables (1-4) (2)
|
Full Article (PDF)-2367K (5)
|
Full Article with Cover (PDF)-2734K (4)
|
Full Article (XML)-267K (1)
|
Audio-860K (2)
|
Peer-Review Report-218K (1)
|
Answering Reviewers-203K (2)
|
Received: 08/14/2025
|
Revised: 09/05/2025
|
Accepted: 12/17/2025
|
RCA
|
CrossRef
|
Google Scholar
|
Times Cited (0)
|
Total Visits (131)
|
Similar Articles (167)
|
Timeline of Article Publication (0)
|
Authors Evaluation (0)
|
Article Quality Tracking (0)
|
What about the content of this article? (0)
|
Cite
|
(0)
|
Open
